Review Article

# Flow cytometry-based diagnosis of primary immunodeficiency diseases

Hirokazu Kanegane [a, *], Akihiro Hoshino [a, b], Tsubasa Okano [a], Takahiro Yasumi [c], Taizo Wada [d], Hidetoshi Takada [e], Satoshi Okada [f], Motoi Yamashita [a], Tzu-wen Yeh [a], Ryuta Nishikomori [c], Masatoshi Takagi [g], Kohsuke Imai [g], Hans D. Ochs [h], Tomohiro Morio [a]

[a] Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
[b] Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
[c] Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan
[d] Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
[e] Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
[f] Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan
[g] Department of Community Pediatrics, Perinatal and Maternal Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
[h] Department of Pediatrics, University of Washington, and Seattle Children's Research Institute, Seattle, WA, USA

## ARTICLE INFO

## ABSTRACT

Primary immunodeficiencies (PIDs) are a heterogeneous group of inherited diseases of the immune system. The definite diagnosis of PID is ascertained by genetic analysis; however, this takes time and is costly. Flow cytometry provides a rapid and highly sensitive tool for diagnosis of PIDs.

Flow cytometry can evaluate specific cell populations and subpopulations, cell surface, intracellular and intranuclear proteins, biologic effects associated with specific immune defects, and certain functional immune characteristics, each being useful for the diagnosis and evaluation of PIDs. Flow cytometry effectively identifies major forms of PIDs, including severe combined immunodeficiency, X-linked agammaglobulinemia, hyper IgM syndromes, Wiskott-Aldrich syndrome, X-linked lymphoproliferative syndrome, familial hemophagocytic lymphohistiocytosis, autoimmune lymphoproliferative syndrome, IPEX syndrome, CTLA 4 haploinsufficiency and LRBA deficiency, IRAK4 and MyD88 deficiencies, Mendelian susceptibility to mycobacterial disease, chronic mucocuneous candidiasis, and chronic granulomatous disease. While genetic analysis is the definitive approach to establish specific diagnoses of PIDs, flow cytometry provides a tool to effectively evaluate patients with PIDs at relatively low cost.

Copyright © 2017, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

* Corresponding author. Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
E-mail address: hkanegane.ped@tmd.ac.jp (H. Kanegane).
Peer review under responsibility of Japanese Society of Allergology.

8; FHL, familial hemophagocytic lymphohistiocytosis; FOXP3, forkhead box P3; HIES, hyper IgE syndrome; HIGM, hyper IgM syndrome; ICOS, inducible co-stimulator; IFN, interferon; iNKT, invariant natural killer T; IPEX, immune dysregulation, polyendocrinopathy, enteropathy, X-linked inheritance syndrome; IRAK4, IL-1 receptor-associated kinase 4; JAK3, Janus kinase 3; LAD, leukocyte adhesion deficiency; LPS, lipopolysaccharide; LRBA, lipopolysaccharide-responsive and beige-like anchor protein; mAb, monoclonal antibody; MSMD, Mendelian susceptibility to mycobacterial disease; MyD88, myeloid differentiation primary response gene 88; NOD, nucleotide-binding and oligomerization domain; PBMCs, peripheral blood mononuclear cells; PIDs, primary immunodeficiency diseases; PNP, purine nucleoside phosphorylase; RAG, recombination activating gene; SAP, SLAM-associated protein; SCID, severe combined immunodeficiency; STAT, signal transducer and activator of transcription; TCR, T-cell receptor; Th, T helper; TLR, Toll-like receptor; TNF, tumor necrosis factor; WAS, Wiskott-Aldrich syndrome; WASp, WAS protein; XIAP, X-linked inhibitor of apoptosis; XLA, X-linked agammaglobulinemia; XLP, X-linked lymphoproliferative syndrome; XLT, X-linked thrombocytopenia; X-SCID, X-linked severe combined immunodeficiency; ZAP70, ζ-chain-associated protein kinase of 70 kDa

## Introduction

Primary immunodeficiency diseases (PIDs) are a heterogenous group of monogenetic disorders of the immune system, resulting in recurrent and/or severe infections, autoimmunity, auto-inflammation, or malignancies. A careful history focused on the types of infectious agents and other complications are important clues to suspect PID. Laboratory investigations including complete blood count, immunoglobulin levels, antibody titers, assessment of neutrophil function and complement components are also important tools to confirm the diagnosis of PID. As the spectrum of PIDs is expanding, it is often difficult to diagnose PIDs based on clinical and conventional laboratory findings alone. The more recently available genetic investigation is a definitive tool for diagnosing PIDs; however, DNA analysis takes time and is expensive. In contrast, technologies that use physical and chemical characteristics of fluorescent-labeled particles in fluid phase passed through lasers are cheeper than gene analysis, although they need experienced and skilled investigators. Thus, flow cytometry may serve as a bridge between conventional immunological testing and DNA sequencing, offering rapid and accurate results based on single cell analysis.[1]

### Application of flow cytometry in the diagnosis of primary immunodeficiency diseases

Flow cytometry is a highly sensitive tool for evaluating the immune system and supporting the diagnosis of PID. The applications of flow cytometry in the evaluation of PIDs are multiplex and include the investigation of specific cell populations and sub-populations, specific cell membrane, intracellular and intranuclear proteins, biologic effects associated with immune defects, and functional immune abnormalities (Table 1).[2]

Quantitative assessment of cell populations and subpopulations is useful for the diagnosis of X-linked agammaglobulinemia (XLA) characterized by the absence of B cells in the peripheral blood. Patients with severe combined immunodeficiency (SCID) lack T cells, while the impact on B and NK cells is variable depending on the genetic defect. Patients with X-linked lymphoproliferative syndrome type 1 (XLP1) have a marked decrease in invariant natural killer T (iNKT) cells. Autoimmune lymphoproliferative syndrome (ALPS) is characterized by increased T-cell receptor (TCR)-α/β-positive double-negative T (DNT) cells. Patients with autosomal dominant hyper IgE syndrome (HIES), and those with chronic mucocutaneous candidiasis (CMCD) present with decreased number of circulating T helper (Th)17 cells.

As specific cell surface proteins are concerned, unique subsets of patients with common variable immunodeficiency (CVID) can be characterized by assessing CD19$^+$ B cells, B-cell activating factor receptor (BAFF-R) on B cells, and the inducible co-stimulator (ICOS) on activated T cells. Patients with X-linked hyper IgM syndrome (X-HIGM) fail to express CD40 ligand (CD40L) on activated T cells, and a group of patients with autosomal recessive hyper IgM syndrome lack CD40 expression on B cells. Mendelian susceptibility to mycobacterial disease (MSMD) has been associated with aberrant interferon (IFN)-γR1 expression on monocytes or deficient IL-12Rβ1 expression on activated T cells. Patients with leukocyte adhesion deficiency type 1 (LAD1) can be identified by absent expression of CD18 on granulocytes. Lymphocytes from patients with X-linked SCID (X-SCID) show deficient CD132 (common γ chain) expression. Patients suffering from gp91-phox- and p22-phox-deficient chronic granulomatous disease (CGD), lacking the

**Table 1**
Application of flow cytometry in the diagnosis of primary immunodeficiency diseases.

| Disease | Test |
|---|---|
| **Evaluate for specific cell population and subpopulation** | |
| XLA | Absent B cells |
| SCID | Absent T cells and variable number of B and NK cells (depending on defect) |
| XLP1 | Markedly reduced iNKT cells |
| ALPS | Increased TCR-$\alpha/\beta+$ double-negative (CD4$^-$CD8$^-$) T cells |
| HIES and CMCD | Decreased Th17 cells |
| **Evaluate of specific cell surface protein** | |
| CVID | CD19 on B cells |
| | BAFF-R on B cells |
| | ICOS on activated T cells |
| X-linked HIGM | CD40L on activated T cells |
| Autosomal recessive HIGM | CD40 on B cells |
| MSMD | IFN-$\gamma$R1 on monocytes |
| | IL-12R$\beta$1 on activated T cells |
| LAD1 | CD18 on granulocytes |
| X-SCID | CD132 on lymphocytes |
| gp91-phox and p22-phox deficient CGD | Cytochrome b558 on granulocytes and B cells |
| IL-17RA deficiency | IL-17RA on lymphocytes and monocytes |
| **Evaluate of specific intracellular protein** | |
| XLA | BTK in monocytes and platelets |
| Wiskott-Aldrich syndrome and X-linked thrombocytopenia | WASp in lymphocytes and myeloid cells |
| XLP1 | SAP in CD8$^+$ T cells and NK cells |
| XLP2 | XIAP in lymphocytes |
| FHL2 | Perforin in CD8$^+$ T cells and NK cells |
| FHL3 | Munc13-4 in platelets |
| ZAP70 deficiency | ZAP70 in T cells |
| p47-phox and p67-phox deficient CGD | p47-phox and p67-phox protein in granulocytes |
| DOCK8 deficiency | DOCK8 in lymphocytes |
| CTLA4 haploinsufficiency and LRBA deficiency | CTLA4 in CD4$^+$FOXP3$^+$ T cells |
| **Evaluate of specific nuclear protein** | |
| IPEX | FOXP3 in CD4$^+$CD25$^+$ T cells |
| **Evaluate biologic effects** | |
| CVID | Decreased switched memory B cells |
| Omenn syndrome and hypomorphic SCID | Oligoclonal TCR/diversity |
| X-linked HIGM | Decreased memory B cells and memory CD4$^+$ T cells |
| **Evaluate function** | |
| MSMD | STAT1 phosphorylation in monocytes in response to IFN-$\gamma$ |
| CMCD (STAT1 gain-of-function) | STAT1 phosphorylation in monocytes in response to IFN-$\gamma$ |
| FHL3/4/5, Chédiak-Higashi syndrome and Griscelli syndrome | CD107a expression in NK cells and CTLs |
| XLP2 | TNF-$\alpha$ in monocytes in response to muramyl dipeptides |
| CGD | DHR123 assay in granulocytes, monocytes and B cells |
| X-SCID and JAK3-deficient SCID | STAT phosphorylation in lymphocytes in response to cytokine stimulation |
| X-linked HIGM | No binding of CD40L and CD40-Ig |
| IRAK4 and MyD88 deficiency | TNF-$\alpha$ in monocytes in response to LPS |
| IL-10R deficiency | STAT3 phosphorylation in lymphocytes in response to IL-10 |
| Infantile-onset multisystem autoimmune disease 1 (heterozygous GOF mutation in STAT 3) | Increased STAT3 phosphorylation |

XLA, X-linked agammaglobulinemia; SCID, severe combined immunodeficiency; XLP, X-linked lymphoproliferative syndrome; iNKT, invariant natural killer T; ALPS, autoimmune lymphoproliferative syndrome; TCR, T-cell receptor; HIES, hyper IgE syndrome; CMCD, chronic mucocutaneous candidiasis disease; CVID, common variable immunodeficiency; BAFF-R, B-cell activating factor receptor; ICOS, inducible co-stimulator; HIGM, hyper IgM syndrome; CD40L, CD40 ligand; MSMD, Mendelian susceptibility to mycobacterial disease; IFN, interferon; IL, interleukin; LAD, leukocyte adhesion deficiency; CGD, chronic granulomatous disease; BTK, Bruton tyrosine kinase; WASp, Wiskott-Aldrich syndrome protein; SAP, signaling activation molecule-associated protein; XIAP, X-linked inhibitor of apoptosis; FHL, familial hemophagocytic lymphohistiocytosis; FOXP3, forkhead box P3; ZAP70, ζ-chain -associated protein kinase of 70 kDa; DOCK8, dedicator of cytokinesis 8; CTLA4, cytotoxic T-lymphocyte-associated protein 4; LRBA, LPS responsive beige-like anchor protein; IPEX, immune dysregulation, polyendocrinopathy, enteropathy, X-linked; STAT, signal transducer and activator of transcription; CTLs, cytotoxic T lymphocytes; DHR, dehydrorhodamine; JAK3, Janus kinase 3; IRAK4, interleukin-1 receptor-associated kinase 4; MyD88, myeloid differentiation primary response gene 88; TNF, tumor necrosis factor; LPS, lypopolysaccharide; GOF, gain-of-function. This table is modified from Reference[2] with permission.

membrane bound cytochrome b558, can be identified using monoclonal antibody (mAb) 7D5 against cytochrome b558 expressed by granulocytes and B cells. Lack of IL-17RA expression on lymphocytes and monocytes is typical for patients with chronic mucocutaneous candida infection and IL-17RA deficiency.

A large number of PIDs can be diagnosed by analyzing expression of specific intracellular proteins. Patients with XLA generally lack Bruton's tyrosine kinase (BTK) expression in monocytes and platelets. Patients suffering from the Wiskott-Aldrich syndrome (WAS) or X-linked thrombocytopenia (XLT) show absent or reduced expression of WAS protein (WASp) in lymphocytes and myeloid cells. Patients with XLP1 lack expression of SLAM-associated protein (SAP) in lymphocytes. Lymphocytes from patients with XLP2 lack expression of X-linked inhibitor of apoptosis (XIAP) protein.

Patients experiencing familial hemophagocytic lymphohistiocytosis type 2 (FHL2) can be identified by absent perforin expression in CD8$^+$ T cells and NK cells. Patients with FHL3 demonstrate reduced expression of Munc13-4 in platelets. Patients with ζ-chain-associated protein kinase of 70 kDa (ZAP70) deficiency lack expression of ZAP70 in lymphocytes. Neutrophils from patients with X-linked CGD lack gp91-phox, and those from patients with autosomal recessive CGD due to p47-phox and p67-phox mutation lack relevant protein expression. Most patients with dedicator of cytokinesis 8 (DOCK8) deficiency lack expression of DOCK8 in lymphocytes. Both cytotoxic T-lymphocyte-associated protein 4 (CTLA4) haploinsufficiency and lipopolysaccharide-responsive and beige-like anchor protein (LRBA) deficiency have in common low CTLA4 expression in CD4$^+$FOXP3$^+$ regulatory T cells. Most patients

**Fig. 1.** Flow cytometry in a patient with X-linked severe combined immunodeficiency. **A**, Patient T cells (CD3$^+$), B cells (CD19$^+$), and NK cells (CD16$^+$CD56$^+$) were separated based on the lymphocyte gate. T and NK cells are absent, and the number of B cells are increased. **B**, CD132 (common γ chain) expression by CD19$^+$ B cells. Patient cells lack CD132 expression. Gray shaded area, isotype control; black line, anti-CD132 staining. **C**, Flow cytometric evaluation of STAT5 phosphorylation following IL-2 stimulation. Patient cells fail to respond. Gray shaded area, no stimulant; black line, 20 min post-IL-2 stimulation. **D**, Flow cytometric evaluation of STAT3 phosphorylation following IL-21 stimulation. Patient cells fail to respond. Gray shaded area, no stimulant; black line, 20 min post-IL-21 stimulation.

presenting with immune dysregulation, polyendocrinopathy, enteropathy, X-linked inheritance syndrome (IPEX) have low or absent nuclear forkhead box P3 (FOXP3) expression by $CD4^+CD25^+$ regulatory T cells.

Flow cytometry techniques are now available to evaluate biologic effects of mutated genes, and the results can be used for the diagnosis of relevant PIDs. Most patients with CVID or hyper IgM syndromes have decreased switched memory B cells. Omenn syndrome and most hypomorphic SCID syndromes are characterized by an oligoclonal T-cell repertoire.

The introduction of functional tests using flow cytometry has provided a powerful tool to evaluate important pathways of cognate and innate immunity. Patients with MSMD due to mutations in genes of the IL12/23-IFNγ pathway can be identified by demonstrating reduced phosphorylation of signal transducer and activator of transcription (STAT)1 expression in response to stimulation with cytokines. Peripheral blood mononuclear cells (PBMCs) from patients with CMCD respond with reduced phosphorylation of STAT1 when stimulated with IFN-γ. Patients with FHL3/4/5, Chédiak-Higashi and Gricelli syndrome demonstrate reduced CD107a expression in resting NK cells and in cytotoxic T lymphocytes (CTLs). Monocytes of patients with XLP2 respond with

reduced tumor necrosis factor (TNF)-α production by monocytes in response to muramyl dipeptide. CGD patients regardless of the molecular defect show reduced or absent dihydrorhodamine (DHR) 123 reduction in granulocytes, monocytes and B cells. Patients with X-SCID and Janus kinase 3 (JAK3)-deficient SCID demonstrate reduced phosphorylation of STAT3 and STAT5 in response to cytokine-stimulation. IL-1 receptor-associated kinase 4 (IRAK4) and myeloid differentiation primary response gene 88 (MyD88) deficiencies can be identified by reduced TNF-α production in monocytes in response to lipopolysaccharide (LPS). Patients with IL-10 receptor deficiency demonstrate reduced STAT3 phosphorylation when stimulated with IL-10. Infantile-onset multisystem autoimmune disease 1, caused by heterozygous gain-of-function mutation in STAT3, is typically associated with increased STAT3 phosphorylation by unstimulated lymphocytes.

The following are examples illustrating the application of flow cytometry for the diagnosis of molecularly defined PIDs.

*Severe combined immunodeficiency*

SCID disorders, the most severe forms of PID, are generally characterized by complete absence of T-cell mediated immunity and impaired B-cell function.[3] Patients with SCID can be classified



**Fig. 2.** Flow cytometry in a patient with X-linked agammaglobulinemia (XLA). **A**, $CD19^+CD20^+$ B cells are markedly reduced. **B**, Bruton's tyrosine kinase (BTK) expression is absent in patient monocytes. A bimodal or mosaic pattern of BTK expression is demonstrated in the heterozygous carrier. Gray shaded area, isotype control; black line, anti-BTK monoclonal antibody.

by immunophenotypic characteristics based on flow cytometry. T⁻B⁻NK⁻ SCID includes reticular dysgenesis and adenosine deaminase (ADA) deficiency. T⁻B⁻NK⁺ SCID suggest mutations affecting the recombination activating genes (*RAG)1* and *RAG2*, Artemis, DNA ligase IV, and Cernunnos. T⁻B⁺NK⁻ phenotype is characteristic for X-SCID and JAK3 deficiency. T⁻B⁺NK⁺ SCID includes IL-7Rα, CD3δ, CD3ε and CD3ζ deficiencies. In X-SCID, representing close to half of all SCID patients,[4] T and NK cells are absent while B cell counts are normal or high (Fig. 1A). The gene responsible for X-SCID is *IL2RG,* coding for the common γ chain (CD132). Therefore, the absence of CD132 by flow cytometry strongly suggests X-SCID (Fig. 1B), although a few patients with mutations in the cytoplasmic domain of the *IL2RG* may express normal CD132. Since the common γ chain is also part of the IL-4, IL-7, IL-9, IL-15, and IL-21 receptors, these cytokines constitute the specific ligands for all pathways that depend on a functional common γ chain. Phosphorylation of intracellular STATs can be evaluated by flow cytometry using mAbs that recognize only STATs that are phosphorylated. As shown in Figure 1C,D, patients with X-SCID have impaired tyrosine phosphorylation of STAT5 and STAT3 in response to stimulation with IL-2 and IL-21, respectively. This assay also identifies JAK3 deficiency because JAK3 interacts intracellularly with the common γ chain. ZAP70 deficiency is a form of SCID characterized by CD8 deficiency; patients with ZAP70 deficiency lack expression of ZAP70 in T cells.[5]

*X-linked agammaglobulinemia*

XLA is characterized by the absence of circulating B cells and severe reduction of all serum immunoglobulins due to mutations in the *BTK* gene. Absent or markedly reduced B cell numbers, determined by flow cytometry based on the lack of CD19- and/or CD20-expressing cells, are typical for all forms of agammaglobulinemia (Fig. 2A). Therefore, assessment of BTK is mandatory for the diagnosis of XLA.[6] Because patients with XLA have no B cells, intracellular BTK expression has to be evaluated in monocytes or platelets (Fig. 2B).[7,8] This technique can also be used for the detection of XLA carriers. Absent of reduced expression of BTK strongly suggests XLA, but normal quantity of BTK does not rule out the diagnosis, as some patients with XLA express normal amount of nonfunctional BTK protein.[9] B cell-deficient patients with wild type *BTK* may have autosomal recessive agammaglobulinemia, and sequence analysis of μ heavy chain, Igα, Igβ, λ5, BLNK, E47 or PI3KR1 is required.

*Hyper IgM syndromes*

HIGM syndromes are a group of genetic disorders affecting molecules involved in B cell class switch recombination and



**Fig. 3.** Flow cytometric identification of CD154 (CD40L) on activated T cells in a patient with X-linked hyper IgM syndrome. **A**, Peripheral blood mononuclear cells were cultured with phorbol myristate acetate and ionomycin for 3.5 h. The cells are CD69-positive, indicating activated T cells, but only control CD69-positive cells express CD152. **B**, CD154 expression on CD3⁺CD8⁻ T cells was evaluated. The patient's cells failed to express CD154. Gray shaded area, isotype control; black line, anti-CD154 monoclonal antibody.

somatic hypermutation.[10] Affected patients present with normal or increased serum IgM, and low levels of IgG and IgA. While mutations in several genes have been associated with HIGM, the most frequently affected gene is *CD40L* with X-linked recessive inheritance. CD40L-deficient patients develop not only bacterial but also opportunistic infections and malignancies, implying the important role of CD40L in T cell function. CD40L (CD154) expression by activated CD4[+] T cells is absent or reduced when assessed by anti-CD40L specific mAbs in most but not all patients with X-linked HIGM (Fig. 3), since some mutations result in non-functional protein that nevertheless can bind to epitope neutral mAbs.[11] In contrast, only functional CD40L can bind to the CD40-Ig construct, providing a flow cytometry-based functional assay for X-linked HIGM.[12] CD40 deficiency, one of several autosomal recessive HIGM syndromes, is a phenocopy of CD40L deficiency that can be identified by assessing CD40 expression on B cells, monocytes, or dendritic cells.[13] Except for CD40L and CD40 deficiency, none of the other HIGM syndrome can be identified by flow cytometry.

### Common variable immunodeficiency

CVID is a heterogenous group of disorders characterized by hypogammaglobulinemia, defective specific antibody production and increased susceptibility to recurrent and chronic infections, and often to autoimmunity, lymphoproliferative disorders and cancer.[14] Patients with CVID have normal or low numbers of B cells. B cells can be subdivided into naïve (CD27[−]IgD[+]IgM[+]), IgM memory (CD27[+]IgD[+]IgM[+]), and switched memory (CD27[+]IgD[−]IgM[−]) B cells based on CD27 and IgD/IgM expression.[15] Most patients with CVID show a decreased number of switched memory B cells. Decreased numbers of switched memory B cells are also observed in HIGM syndromes.[16]

A small subset of CVID are caused by mutations in *ICOS*, *CD19*, and *BAFFR* (*TNFRSF13C*). These patients can be screened by flow cytometry. Patients with ICOS deficiency were reported to have reduced up-regulation of ICOS by activated T cells.[17] BAFFR is constitutively expressed on B cells, and patients with *BAFFR* mutations show reduced expression of this protein.[18] CD19 forms complexes with CD21, CD81, and CD225 which collaborate with the B cell receptor upon antigen recognition. Absence of CD19 expression on B cells has been observed in patients with CD19 and CD81 deficiencies.[19–21]

### Wiskott-Aldrich syndrome and X-linked thrombocytopenia

WAS is a rare X-linked disorder characterized by persistent microthrombocytopenia, eczema, cellular and humoral immunodeficiency, and an increased risk of autoimmune disease and hematologic malignancy.[22] WAS is caused by mutations in the *WAS* gene encoding the WASp; this gene is also responsible for XLT and X-linked neutropenia. Monoclonal antibodies against WASp are useful for screening patients suspected to have WAS or XLT (Fig. 4).[23,24] This technique is also of value in the evaluation of chimerism after hematopoietic stem cell transplantation and somatic reversion mosaicism of the *WAS* gene.[25,26]

### X-linked lymphoproliferative syndrome

XLP, a rare PID with susceptibility to Epstein–Barr virus infection, is clinically characterized by hemophagocytic lymphohistiocytosis and hypogammaglobulinemia, with or without lymphoma. XLP is classified into type 1 (XLP1) caused by mutations in the *SH2D1A* gene encoding SAP and type 2 (XLP2) caused by mutations in the *XIAP* or *BIRC4* gene encoding XIAP. Flow cytometric detection of intracellular SAP and XIAP proteins are useful screening tests for the identification of patients with XLP1 and XLP2, respectively



**Fig. 4.** Flow cytometric detection of WASp in a patient with Wiskott-Aldrich syndrome. Cytoplasmic WASp expression was markedly reduced in patient CD3[+] T cells, CD19[+] B cells, and CD14[+] monocytes. Gray shaded area, isotype control; black line, anti-WASp mAb.

**Fig. 5.** Flow cytometry in patients with X-linked lymphoproliferative syndrome type 1 (XLP1) and XLP2. **A**, SAP expression was markedly reduced in CD8+ T cells and CD56+ NK cells from a patient with XLP1. **B**, XIAP expression was reduced in lymphocytes and monocytes from a patient with XLP2. Gray shaded area, isotype control; black line, anti-SAP or anti-XIAP monoclonal antibody.

(Fig. 5A,B).[27,28] While patients with XLP1 have extremely reduced numbers of iNKT cells, patients with XLP2 have variable low numbers of iNKT cells. Flow cytometry is also useful to identify atypical cases of XLP including somatic reversion mosaicism of XLP1, and female XLP2.[29,30] Because XIAP plays an essential role in nucleotide-binding oligomerization domain protein (NOD)1/2 signaling, flow cytometric assessment of TNF-α production by monocytes in response to NOD2 stimulation by muramyl dipeptide is a useful functional approach for diagnosing XIAP deficiency. TNF-α production was found to be severely diminished in all patients with XIAP deficiency studied.[31]

*Familial hemophagocytic lymphohistiocytosis*

FHL is a group of genetically determined, life-threatening disorders associated with the uncontrolled proliferation of activated lymphocytes and histiocytes secreting large amounts of inflammatory cytokines.[32] Genetic defects affecting granule-mediated cytotoxicity are associated with FHL, including perforin (FHL2), Munc13-4 (FHL3), syntaxin 11 (FHL4), and Munc 18-2 (FHL5) deficiencies. FHL2 can be evaluated by assessing perforin expression in CD56+CD16+ NK cells and CD8+ T cells (Fig. 6A),[33] and FHL3 can be screened by detecting Munc13-4 expression in platelets (Fig. 6B).[34] Assessment of the release of cytolytic granules by measuring surface expression of CD107a by NK or cytotoxic T cells is useful for the diagnosis of FHL3.[35,36] This assay has also been suggested for the diagnosis of FHL 4, FHL5, Chédiak-Higashi syndrome and Griscelli syndrome, all having in common defects in granule-mediated cytotoxic pathways.[37]

*Autoimmune lymphoproliferative syndrome*

ALPS is a disorder of lymphocyte homeostasis characterized by chronic non-malignant lymphoproliferation, autoimmune manifestations (mainly autoimmune cytopenia) and an increased incidence of lymphoid malignancies.[38] Most patients with ALPS harbor mutations in genes which regulate the extrinsic Fas-mediated programmed cell death pathway (*FAS*, *FASLG* and *CASP10*). An immunological hallmark of this syndrome is the increased level of circulating TCR-α/β+CD4−CD8− T cells, referred to as DNT cells (Supplementary Fig. 1A). While control T cells undergo robust apoptosis as shown by annexin V-positive cells following stimulation with anti-FAS antibody, ALPS patient T cells do not (Supplementary Fig. 1B).

*IPEX syndrome*

IPEX syndrome, a rare X-linked autoimmune disorder caused by mutations in the *FOXP3* gene, is characterized by severe enteropathy, endocrinopathies (diabetes and/or thyroiditis), and eczematous dermatitis.[39] FOXP3 plays a critical role in the development



Fig. 6. Flow cytometric detection of patients with FHL2 and FHL3. **A**, Reduced perforin expression in NK cells (CD3−CD56+CD16+ lymphocyte population) from a FHL2 patient. Solid histograms represents staining with isotype control antibody and open histograms represent staining with anti-perforin antibody. **B**, Reduced Munc13-4 expression in platelets (CD41a+ population) from a FHL3 patient. Solid histograms represent staining with control rabbit serum and open histograms represents staining with anti-Munc13-4 rabbit antibody.

**Fig. 7.** Flow cytometric analysis of dihydrorhodamine (DHR) oxidation and expression of p47phox, p67phox and gp91phox in CGD patients and a carrier mother. In the DHR assay, granulocytes were analyzed using DHR123 as a fluorescent probe before (solid histogram) and after (open histogram) stimulation with phorbol myristate acetate (first column of panels). Expression of gp91phox in patient granulocytes, as assessed using 7D5 (second column of panels). Expression of p47phox and p67phox in CD14+ monocytes are shown in third and fourth column. Solid histograms indicate isotype control antibody and open histograms represent anti-subunit monoclonal antibodies.

and function of CD4+CD25+ regulatory T (Treg) cells. Most IPEX patients lack or have reduced numbers of CD4+CD25+FOXP3+ or CD4+CD25+CD127low Treg cells. Interestingly, a sufficient number of CD4+CD25+CD127low cells were observed in patients with hypomorphic *FOXP3* mutations.[40] Because CD25 (α chain of the IL-2 receptor) and STAT5b affect Treg development and function, patients with CD25 or STAT5b mutations present with an IPEX-like phenotype.[41,42] Although reduced in number, Treg cells from these patients express FOXP3.

### CTLA4 haploinsufficiency and LRBA deficiency

CTLA4 is a costimulatory molecule expressed by activated T cells, and, similar to the T-cell costimulatory molecule CD28, binds to B7-1 (CD80) and B7-2 (CD86) on the surface of antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Heterozygous loss-of-function mutations in the *CTLA4* gene have been identified in CVID patients with IPEX-like phenotype including enteropathy and autoimmune cytopenias.[43,44] Patients with CTLA4 haploinsufficiency show reduced expression of CTLA4 in activated CD4+FOXP3+ T cells (Supplementary Fig. 2). Biallelic loss-of-function mutations in *LRBA* were identified in patients with the clinical diagnosis of CVID with

ALPS- or IPEX-like manifestations.[45,46] A common denominator is early onset of severe autoimmunity, often associated with recurrent infections and lymphoproliferative disease with increased risk of lymphoma. Because LRBA colocalizes with CTLA4 in endosomal vesicles, LRBA deficiency increases CTLA4 turnover, resulting in reduced levels of CTLA4 protein in FOXP3+ regulatory and activated conventional T cells.[47] The phenotypic similarity between LRBA and CTLA4 deficiencies may be explained by this common defect in CTLA4 expression.

### IRAK4 and MyD88 deficiency

IRAK4 is a kinase that plays a crucial role in Toll-like receptor (TLR) and IL-1 receptor signaling. Ligand binding to these receptors triggers the recruitment of the adaptor proteins MyD88, IRAK4, and IRAK1, resulting in downstream signal transduction. Autosomal recessive IRAK4 and MyD88 deficiency impair TLR and IL-1 receptor-mediated immunity, resulting in invasive bacterial, especially pneumococcal infections.[48] Intracellular TNF-α production in monocytes in response to LPS (a TLR4 ligand) was assayed by flow cytometry and found to be diminished in patients with IRAK4 deficiency (Supplementary Fig. 3).[49] This assay may also be useful for the screening of patients with MyD88 deficiency.

## Mendelian susceptibility to mycobacterial disease

MSMD represents a group of PIDs characterized by vulnerability to infection with weakly virulent mycobacteria and Salmonella.[50] Affected patients may have mutations in genes involved in the IL-12/23-IFN-γ pathway. Patients with IL-12Rβ1 and IFNγR1 deficiencies can be screened by flow cytometry. Most patients with IL-12Rβ1 and autosomal recessive IFNγR1 deficiencies demonstrate absence of cell surface protein. In contrast, IFNγR1 expression was increased in a patient with autosomal dominant form of IFNγR1 deficiency due to overexpression of the abnormal IFNγR1 chain (Supplementary Fig. 4).

## Chronic mucocutaneous candidiasis

CMCD is characterized by persistent or recurrent *C. albicans* infections of skin, nail, and mucosal membranes.[51] CMCD refers to a hetergenous group of PIDs including autosomal dominant HIES associated with heterozygous *STAT3* mutation, IL-12p40 deficiency, IL-12Rβ1 deficiency, and autoimmune polyendocrinopathy-candidiasis—ectodermal dystrophy/dysplasia (APECED). Patients with CMCD often have decreased levels of Th17 cells, as do patients with HIES.[52] Those with APECED may develop neutralizing autoantibodies against IL-17A, IL-17F, and/or IL-22, explaining the development of CMCD. Of the recently discovered autosomal recessive IL-17RA and autosomal dominant IL-17F deficiencies associated with CMCD,[53] IL-17RA deficiency can be readily diagnosed by the absence of IL-17RA on the surface of circulating lymphocytes and monocytes.[54] The most common cause of CMCD are heterozygous gain-of-function mutations in *STAT1*.[55,56] Flow analysis readily recognizes elevated levels of phosphorylated STAT1 that persist following IFN-γ stimulation of monocytes from patients with *STAT1* gain-of-function mutations (Supplementary Fig. 5).[57] In contrast to control cells, the tyrosine kinase inhibitor, staurosporine, did not reduce STAT1 phosphorylation in monocytes obtained from patients with STAT1 gain-of-function mutations.

## Chronic granulomatous disease

CGD is a genetically heterogeneous PID affecting bactericidal function of phagocytes and characterized by recurrent bacterial and fungal infections. CGD is caused by defects in the NADPH oxidase complex, which is responsible for the phagocyte respiratory burst leading to the generation of superoxide and other reactive oxygen species. Mutations in five components (gp91$^{phox}$, p22$^{phox}$, p47$^{phox}$, p67$^{phox}$, and p40$^{phox}$) of the NADPH complex account for the X-linked and autosomal recessive forms of CGD. Laboratory diagnosis of CGD is performed by the measurement of superoxide production, and is evaluated by flow cytometry using DHR123 oxidation (Fig. 7). This method allows the distinction between X-linked and autosomal recessive CGD, and detection of carriers of X-linked CGD.[58] Subtypes of CGD can be determined by genetic as well as flow cytometric analysis. The 7D5 mAb recognizes the surface components of NADPH oxidase, and patients with gp91$^{phox}$ and p22$^{phox}$ deficiencies can be diagnosed using this antibody (Fig. 7).[59] Patients with p47$^{phox}$ and p67$^{phox}$ deficiencies can be identified with intracellular staining using anti-p47$^{phox}$ and p67$^{phox}$ specific monoclonal antibodies, respectively.[60]

All the staining protocols are available in Supplementary Methods.

## Conclusion

Flow cytometry is an instrumental tool for the evaluation and diagnosis of PIDs. The use of flow cytometry provides rapid results and often suggests the correct diagnosis. While genetic analysis delivers a definitive diagnosis, flow cytometry plays an important role in the cost-effective evaluation of patients suspected to have PID.

## Appendix A. Supplementary data

*Authors' contributions*
HK designed the study and wrote the manuscript. AH, TO, TYa, TW, TH and SO performed the flow cytometry and wrote the draft. MY and TYe performed the flow cytometric analysis and collected the data. RN, MT, KI, HDO and TM contributed to critical discussion. All authors read and approved the final manuscript.

## References

1. Givan AL. Flow cytometry: an introduction. *Methods Mol Biol* 2004;**263**:1—32.
2. Oliveira JB, Fleisher TA. Molecular- and flow cytometry-based diagnosis of primary immunodeficiency disorders. *Curr Allergy Asthma Rep* 2010;**10**:460—7.
3. Chinn IK, Shearer WT. Severe combined immunodeficiency disorders. *Immunol Allergy Clin North Am* 2015;**35**:671—94.
4. Buckley RH, Schiff RI, Schiff SE, Markert K, Williams LW, Harville TO, et al. Human severe combined immunodeficiency (SCID): genetic, phenotypic and functional diversity in 108 infants. *J Pediatr* 1997;**130**:378—87.
5. Turul T, Tezcan I, Artac H, de Bruin-Versteeg S, Barendregt BH, Reisli I, et al. Clinical heterogeneity can hamper the diagnosis of patients with ZAP70 deficiency. *Eur J Pediatr* 2009;**168**:87—93.
6. Conley ME, Broides A, Hernandez-Trujillo V, Howard V, Kanegane H, Miyawaki T, et al. Genetic analysis of patients with defects in early B-cell development. *Immunol Rev* 2005;**203**:216—34.
7. Futatani T, Miyawaki T, Tsukada S, Hashimoto S, Kunikata T, Arai S, et al. Deficient expression of Bruton's tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection. *Blood* 1998;**91**:595—602.
8. Futatani T, Watanabe C, Baba Y, Tsukada S, Ochs HD. Bruton's tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females. *Br J Haematol* 2001;**114**:141—9.
9. Kanegane H, Futatani T, Wang Y, Nomura K, Shinozaki K, Matsukura H, et al. Clinical and mutational characteristics of X-linked agammaglobulinemia and its carrier identified by flow cytometric assessment combined with genetic analysis. *J Allergy Clin Immunol* 2001;**108**:1012—20.
10. Gulino AV, Notarangelo LD. Hyper IgM syndromes. *Curr Opin Rheumatol* 2003;**15**:422—9.
11. Lee WI, Torgerson TR, Schumacher MJ, Yel L, Zhu Q, Ochs HD. Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. *Blood* 2005;**105**:1881—90.
12. Semaya K, Nonoyama S, Gangsaas I, Hollenbaught D, Pabst HF, Aruffo A, et al. Mutations of the *CD40 ligand* gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome. *Blood* 1998;**92**:2421—34.
13. Ferrari S, Giliani S, Insalaco A, Al-Ghonaium A, Soresina AR, Loubser M, et al. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. *Proc Natl Acad Sci U S A* 2001;**98**:12614—9.
14. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. *Clin Immunol* 1999;**92**:34—48.
15. Warnatz K, Denz A, Dräger R, Braun M, Groth C, Wolff-Vorbeck G, et al. Severe deficiency of switched memory B cells (CD27$^+$IgM$^-$IgD$^-$) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. *Blood* 2002;**99**:1544—51.
16. Agematsu K, Nagumo H, Shinozaki K, Hokibara S, Yasui K, Terada K, et al. Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM syndrome. *J Clin Invest* 1998;**102**:853—60.
17. Grimbacher B, Hutloff A, Schlesier M, Glocker E, Warnatz K, Dräger R, et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. *Nat Immunol* 2003;**4**:261—8.
18. Warnatz K, Salzer U, Rizzi M, Fischer B, Gutenberger S, Böhm J, et al. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. *Proc Natl Acad Sci U S A* 2009;**106**:13945—50.

19. van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006;**354**:1901–12.

20. Kanegane H, Agematsu K, Futatani T, Sira MM, Suga K, Sekiguchi T, et al. Novel mutations in a Japanese patient with CD19 deficiency. Genes Immun 2007;**8**:663–70.

21. van Zelm MC, Smet J, Adams B, Mascart F, Schandené L, Janssen F, et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest 2010;**120**:1265–74.

22. Notarangelo LD, Miao CH, Ochs HD. Wiskott-Aldrich syndrome. Curr Opin Hematol 2008;**15**:30–6.

23. Kawai S, Minegishi M, Ohashi Y, Sasahara Y, Kumaki S, Konno T, et al. Flow cytometric determination of intracytoplasmic Wiskott-Aldrich syndrome protein in peripheral blood lymphocyte subpopulations. J Immunol Methods 2002;**260**:195–205.

24. Kanegane H, Nomura K, Miyawaki T, Sasahara Y, Kawai S, Tsuchiya S, et al. X-linked thrombocytopenia identified by flow cytometric demonstration of defective Wiskott-Aldrich syndrome protein in lymphocytes. Blood 2000;**95**:1110–1.

25. Yamaguchi K, Ariga T, Yamada M, Nelson DL, Kobayashi R, Kobayashi C, et al. Mixed chimera status of 12 patients with Wiskott-Aldrich syndrome (WAS) after hematopoietic stem cell transplantation: evaluation by flow cytometric analysis of intracellular WAS protein expression. Blood 2002;**100**:1208–14.

26. Wada T, Schurman SH, Otsu M, Garabedian EK, Ochs HD, Nelson DL, et al. Somatic mosaicism in Wiskott–Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc Natl Acad Sci U S A 2001;**98**:8697–702.

27. Shinozaki K, Kanegane H, Matsukura H, Sumazaki R, Tsuchida M, Makita M, et al. Activation-dependent T cell expression of the X-linked lymphoproliferative disease gene product SLAM-associated protein and its assessment for patient detection. Int Immunol 2002;**14**:1215–23.

28. Marsh RA, Villanueva J, Zhang K, Snow AL, Su HC, Madden L, et al. A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency. Cytometry B Clin Cytom 2009;**76**:334–44.

29. Palendira U, Low C, Bell AI, Ma CS, Abbott RJ, Phan TG, et al. Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus. J Exp Med 2012;**209**:913–24.

30. Yang X, Hoshino A, Taga T, Kunitsu T, Ikeda Y, Yasumi T, et al. A female patient with incomplete hemophagocytic lymphohistiocytosis caused by a heterozygous XIAP mutation associated with non-random X-chromosome inactivation skewed towards the wild-type XIAP allele. J Clin Immunol 2015;**35**:244–8.

31. Ammann S, Elling R, Gyrd-Hansen M, Dückers G, Bredius R, Burns SO, et al. A new functional assay for the diagnosis of X-linked inhibitor of apoptosis (XIAP) deficiency. Clin Exp Immunol 2014;**176**:394–400.

32. Deger B. Familial hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 2015;**29**:903–13.

33. Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood 2002;**99**:61–6.

34. Murata Y, Yasumi T, Shirakawa R, Izawa K, Sakai H, Abe J, et al. Rapid diagnosis of FHL3 by flow cytometric detection of intraplatelet Munc13-4 protein. Blood 2011;**118**:1225–30.

35. Marcenaro S, Gallo F, Martini S, Santoro A, Griffiths GM, Aricó M, et al. Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood 2006;**108**:2316–23.

36. Hori M, Yasumi T, Shimodera S, Shibata H, Hiejima E, Oda H, et al. A CD57+ CTL degranulation assay effectively identifies familial hemophagocytic lymphohistiocytosis type 3 patients. J Clin Immunol 2017;**37**:92–9.

37. Bryceson YT, Pende D, Maul-Pavicic A, Gilmour KC, Ufheil H, Vraetz T, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 2012;**119**:2754–63.

38. Shah S, Wu E, Rao VK, Tarrant TK. Autoimmune lymphoproliferative syndrome: an update and review of the literature. Curr Allergy Asthma Rep 2014;**14**:462.

39. Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol 2007;**120**:744–50.

40. Otsubo K, Kanegane H, Kamachi Y, Kobayashi I, Tsuge I, Imaizumi M, et al. Identification of FOXP3-negative regulatory T-like (CD4+CD25+CD127low) cells in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Clin Immunol 2011;**141**:111–20.

41. Caudy AA, Reddy ST, Chatila T, Atkinson JP, Verbsky JW. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol 2007;**119**:482–7.

42. Bernasconi A, Marino R, Ribas A, Rossi J, Ciaccino M, Oleastro M, et al. Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation. Pediatrics 2006;**118**:e1584-92.

43. Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 2014;**345**:1623–7.

44. Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 2014;**20**:1410–6.

45. Lopez-Herrera G, Tampella G, Pan-Hammarström Q, Herholz P, Trujillo-Vargas CM, Phadwal K, et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet 2012;**90**:986–1001.

46. Alangari A, Alsultan A, Adly N, Massaad MJ, Kiani IS, Aljebreen A, et al. LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency. J Allergy Clin Immunol 2012;**130**:481–8.e2.

47. Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, et al. Autoimmune disease. patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 2015;**349**:436–40.

48. Picard C, von Bernuth H, Ghandil P, Chrabieh M, Levy O, Arkwright PD, et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) 2010;**89**:403–25.

49. Takada H, Yoshikawa H, Imaizumi M, Kitamura T, Takeyama J, Kumaki S, et al. Delayed separation of the umbilical cord in two siblings with Interleukin-1 receptor-associated kinase 4 deficiency: rapid screening by flow cytometer. J Pediatr 2006;**148**:546–8.

50. Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. Semin Immunol 2016;**26**:454–70.

51. Glocker E, Grimbacher B. Chronic mucocutaneous candidiasis and congenital susceptibility to Candida. Curr Opin Allergy Clin Immunol 2010;**10**:542–50.

52. Takashima T, Okamura M, Yeh T-W, Okano T, Yamashita M, Tanaka K, et al. Multicolor flow cytometry for the diagnosis of primary immunodeficiency diseases. J Clin Immunol 2017;**37**:486–95.

53. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors ofinterleukin-17 immunity. Science 2011;**332**:65–8.

54. Lévy R, Okada S, Béziat V, Moriya K, Liu C, Chai LY, et al. Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency. Proc Natl Acad Sci U S A 2016;**113**:E8277–85.

55. Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, Abhyankar A, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011;**208**:1635–48.

56. Van de Veerdonk FL, Plantinga TS, Hoischen A, Smeekens SP, Joosten LA, Gilissen C, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011;**365**:54–61.

57. Mizoguchi Y, Tsumura M, Okada S, Hirata O, Minegishi S, Imai K, et al. Simple diagnosis of STAT1 gain-of-function alleles in patients with chronic mucocutaneous candidiasis. J Leukoc Biol 2014;**95**:667–76.

58. Vowells SJ, Sekhsaria S, Malech HL, Shalit M, Fleisher TA. Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescence probes. J Immunol Methods 1995;**178**:89–97.

59. Nakamura M, Murakami M, Koga T, Tanaka Y, Minakami S. Monoclonal antibody 7D5 raised to cytochrome b558 of human neutrophils: immunocytochemical detection of the antigen in peripheral phagocytes of normal subjects, patients with chronic granulomatous disease, and their carrier mothers. Blood 1987;**69**:1404–8.

60. Wada T, Muraoka M, Toma T, Imai T, Shigemura T, Agematsu K, et al. Rapid detection of intracellular p47phox and p67phox by flow cytometry; useful screening tests for chronic granulomatous disease. J Clin Immunol 2013;**33**:857–64.